Chronic Idiopathic Myelofibrosis (CIMF)
The incidence is estimated at 0.5–1.5 per 100,000 per year. The majority of patients are aged 50–70 years. In patients with CIMF, the risk of progression to AML is 10–20%. Chromosomal abnormalities are observed in 40–50% of cases.
A. Conventional Cytogenetic Analysis
- Bone marrow karyotype
- Peripheral blood karyotype without stimulation
B. Molecular Cytogenetic Analysis (FISH)
- Detection of deletion of chromosome 20, del(20q12)
- Detection of trisomy 8
- Detection of trisomy 9
- Detection of trisomy 21
- Detection of deletion of chromosome 13, del(13q14)
- Detection of monosomy or deletion of chromosome 7, -7/del(7q-)
- Detection of monosomy or deletion of chromosome 5, -5/del(5q-)
- Detection of deletion of chromosome 17, del(17p13.1), p53 gene
- Detection of translocation t(9;22)(q34;q11), BCR/ABL1
C. Molecular Genetic Analysis
- Detection of the JAK2 gene V617F point mutation
